Prospective observational study of step-up dose treatment with onabotulinumtoxinA in patients with spasticity
DOI:
https://doi.org/10.2340/jrm.v58.45826Keywords:
spasticity, botulinum toxin injection, observational studyAbstract
Objective: To evaluate the safety and effectiveness of “step-up dose” onabotulinumtoxinA (401–600 units per treatment session) in patients with upper and lower limb spasticity.
Design: Multicentre, prospective, observational, single-arm investigation.
Subjects: A convenience sample of 109 patients with upper and lower limb spasticity scheduled to receive their first or second step-up dose onabotulinumtoxinA.
Methods: The study primarily evaluated the safety of step-up dose onabotulinumtoxinA by summarizing adverse events. Effectiveness was evaluated as a secondary objective.
Results: Of the safety population comprising 107 patients, 49 (45.8%) experienced at least 1 adverse event, with coronavirus disease 2019 and nasopharyngitis being the most frequent. Five patients (4.7%) reported adverse events related to onabotulinumtoxinA or injection procedure. These safety findings were generally consistent with those previously reported, while reduction of muscle tone and subsequent clinical benefits were suggested by the Modified Ashworth Scale and patient/physician-reported outcomes.
Conclusion: To the best of our knowledge, this is the first study to prospectively evaluate the safety and effectiveness of onabotulinumtoxinA at doses above 400 units given simultaneously for upper and lower limb spasticity. No new safety concern was identified for this “step-up dose” treatment.
Downloads
References
Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: disordered motor control. Chicago: Year Book Medical Publishers; 1980, pp. 485–494.
Lundström E, Smits A, Borg J, Terént A. Four-fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity: the first year after the event. Stroke 2010; 41: 319–324. DOI: https://doi.org/10.1161/STROKEAHA.109.558619
Ashford S, Turner-Stokes L, editors. Spasticity in adults: management using botulinum toxin – national guidelines. London: Royal College of Physicians; 2018.
Baker JA, Pereira G. The efficacy of botulinum toxin A for spasticity and pain in adults: a systematic review and meta-analysis using the Grades of Recommendation, Assessment, Development and Evaluation approach. Clin Rehabil 2013; 27: 1084–1096. DOI: https://doi.org/10.1177/0269215513491274
Baker JA, Pereira G. The efficacy of botulinum toxin A on improving ease of care in the upper and lower limbs: a systematic review and meta-analysis using the Grades of Recommendation, Assessment, Development and Evaluation approach. Clin Rehabil 2015; 29: 731–740. DOI: https://doi.org/10.1177/0269215514555036
Baker JA, Pereira G. The efficacy of botulinum toxin A for limb spasticity on improving activity restriction and quality of life: a systematic review and meta-analysis using the GRADE approach. Clin Rehabil 2016; 30: 549–558. DOI: https://doi.org/10.1177/0269215515593609
Abo M, Shigematsu T, Hara H, Matsuda Y, Nimura A, Yamashita Y, et al. Efficacy and safety of onabotulinumtoxinA 400 units in patients with post-stroke upper limb spasticity: final report of a randomized, double-blind, placebo-controlled trial with an open-label extension phase. Toxins 2020; 12: 127. DOI: https://doi.org/10.3390/toxins12020127
Wein T, Esquenazi A, Jost WH, Ward AB, Pan G, Dimitrova R. OnabotulinumtoxinA for the treatment of poststroke distal lower limb spasticity: a randomized trial. PM R 2018; 10: 693–703. DOI: https://doi.org/10.1016/j.pmrj.2017.12.006
Watkins CL, Leathley MJ, Gregson JM, Moore AP, Smith TL, Sharma AK. Prevalence of spasticity post stroke. Clin Rehabil 2002; 16: 515–522. DOI: https://doi.org/10.1191/0269215502cr512oa
Lundström E, Terént A, Borg J. Prevalence of disabling spasticity 1 year after first-ever stroke. Eur J Neurol 2008; 15: 533–539. DOI: https://doi.org/10.1111/j.1468-1331.2008.02114.x
Urban PP, Wolf T, Uebele M, Marx JJ, Vogt T, Stoeter P, et al. Occurrence and clinical predictors of spasticity after ischemic stroke. Stroke 2010; 41: 2016–2020. DOI: https://doi.org/10.1161/STROKEAHA.110.581991
Baricich A, Grana E, Carda S, Santamato A, Cisari C, Invernizzi M. High doses of onabotulinumtoxinA in post-stroke spasticity: a retrospective analysis. J Neural Transm 2015; 122: 1283–1287. DOI: https://doi.org/10.1007/s00702-015-1384-6
Chiu SY, Patel B, Burns MR, Legacy J, Wagle Shukla A, Ramirez-Zamora A, et al. High-dose botulinum toxin therapy: safety, benefit, and endurance of efficacy. Tremor Other Hyperkinet Mov 2020;10. DOI: https://doi.org/10.5334/tohm.527
Kirshblum S, Solinsky R, Jasey N, Hampton S, Didesch M, Seidel B, et al. Adverse event profiles of high dose botulinum toxin injections for spasticity. PM R 2020; 12: 349–355. DOI: https://doi.org/10.1002/pmrj.12240
Pandyan AD, Johnson GR, Price CI, Curless RH, Barnes MP, Rodgers H. A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clin Rehabil 1999; 13: 373–383. DOI: https://doi.org/10.1191/026921599677595404
Aloraini SM, Gäverth J, Yeung E, MacKay-Lyons M. Assessment of spasticity after stroke using clinical measures: a systematic review. Disabil Rehabil 2015; 37: 2313–2323. DOI: https://doi.org/10.3109/09638288.2015.1014933
Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67: 206–207. DOI: https://doi.org/10.1093/ptj/67.2.206
Kimura A, Abo M, Masakado Y, Yamashita Y, Maeda T. An investigation into the clinical use of botulinum toxin type A to treat post-stroke hemiplegic patients with upper and/or lower limb spasticity. Jpn J Rehabil Med 2015; 52: 421–430 [in Japanese]. DOI: https://doi.org/10.2490/jjrmc.52.421
Francisco GE, Jost WH, Bavikatte G, Bandari DS, Tang SFT, Munin MC, et al. Individualized onabotulinumtoxinA treatment for upper limb spasticity resulted in high clinician- and patient-reported satisfaction: long-term observational results from the ASPIRE study. PM R 2020; 12: 1120–1133. DOI: https://doi.org/10.1002/pmrj.12328
Sugimoto K, Yamashita Y, Hara T, Yoshida P. Safety and efficacy of botulinum toxin type A (BOTOX) in patients with spasticity: results of special drug use investigation. Prog Med 2015; 35: 1477–1490 [in Japanese].
Esquenazi A, Bavikatte G, Bandari DS, Jost WH, Munin MC, Tang SFT, et al. Long-term observational results from the ASPIRE study: onabotulinumtoxinA treatment for adult lower limb spasticity. PM R 2021; 13: 1079–1093. DOI: https://doi.org/10.1002/pmrj.12517
Varghese-Kroll E, Elovic EP. Contralateral weakness and fatigue after high-dose botulinum toxin injection for management of poststroke spasticity. Am J Phys Med Rehabil 2009; 88: 495–499. DOI: https://doi.org/10.1097/PHM.0b013e3181a5b056
Thomas AM, Simpson DM. Contralateral weakness following botulinum toxin for poststroke spasticity. Muscle Nerve 2012; 46: 443–448. DOI: https://doi.org/10.1002/mus.23492
Esquenazi A. Improvements in healthcare and cost benefits associated with botulinum toxin treatment of spasticity and muscle overactivity. Eur J Neurol 2006; 13 (Suppl 4): 27–34. DOI: https://doi.org/10.1111/j.1468-1331.2006.01651.x
Ayyoub Z, Brashear A, Banach M, Schoene R, Stringer W, Boodhoo T, et al. Safety and stability of pulmonary function in patients with decreased respiratory function treated for spasticity with onabotulinumtoxinA. Toxins 2020; 12: 661. DOI: https://doi.org/10.3390/toxins12100661
Mathevon L, Declemy A, Laffont I, Perennou D. Immunogenicity induced by botulinum toxin injections for limb spasticity: a systematic review. Ann Phys Rehabil Med 2019; 62: 241–251. DOI: https://doi.org/10.1016/j.rehab.2019.03.004
Albright AL, Barron WB, Fasick MP, Polinko P, Janosky J. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 1993; 270: 2475–2477. DOI: https://doi.org/10.1001/jama.1993.03510200081036
Yablon SA, Brin MF, VanDenburgh AM, Zhou J, Garabedian-Ruffalo SM, Abu-Shakra S, et al. Dose response with onabotulinumtoxinA for post-stroke spasticity: a pooled data analysis. Mov Disord 2011; 26: 209–215. DOI: https://doi.org/10.1002/mds.23426
Chen CL, Chen CY, Chen HC, Wu CY, Lin KC, Hsieh YW, et al. Responsiveness and minimal clinically important difference of Modified Ashworth Scale in patients with stroke. Eur J Phys Rehabil Med 2019; 55: 754–760. DOI: https://doi.org/10.23736/S1973-9087.19.05545-X
Jacinto J, Varriale P, Pain E, Lysandropoulos A, Esquenazi A. Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in spasticity. Front Neurol 2020; 11: 388. DOI: https://doi.org/10.3389/fneur.2020.00388
Barnes M, Kocer S, Murie Fernandez M, Balcaitiene J, Fheodoroff K. An international survey of patients living with spasticity. Disabil Rehabil 2017; 39: 1428–1434. DOI: https://doi.org/10.1080/09638288.2016.1198432
Downloads
Additional Files
Published
How to Cite
License
Copyright (c) 2026 Masahiro Abo, Shinichiro Kawakita, Naohisa Kikuchi, Nobuyuki Sasaki, Takashi Shigematsu, Naho Ohyanagi, Yumi Yamazaki, Takao Mogi, Yoshiyuki Yamashita, Ai Hayashi
This work is licensed under a Creative Commons Attribution 4.0 International License.
All digitalized JRM contents is available freely online. The Foundation for Rehabilitation Medicine owns the copyright for all material published until volume 40 (2008), as from volume 41 (2009) authors retain copyright to their work and as from volume 49 (2017) the journal has been published Open Access, under CC-BY-NC licences (unless otherwise specified). The CC-BY-NC licenses allow third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
From 2024, articles are published under the CC-BY licence. This license permits sharing, adapting, and using the material for any purpose, including commercial use, with the condition of providing full attribution to the original publication.
